We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+1.74%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.1B
AUM Growth
+$59.7M
Cap. Flow
-$1.53B
Cap. Flow %
-21.52%
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.6M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$22.5M
4
DYAX
DYAX CORPORATION
DYAX
+$15.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.6M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$220M
2
GILD icon
Gilead Sciences
GILD
+$48M
3
PCYC
PHARMACYCLICS INC
PCYC
+$35.3M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 44.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$922M 13%
8,719,218
-290,993
-3% -$35.3M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$827M 11.66%
20,735,926
+1,412,979
+7% +$57.7M
INCY icon
3
Incyte
INCY
$25.5B
$750M 10.57%
14,810,559
– –
GEVA
4
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$665M 9.37%
10,273,182
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.42B
$499M 7.03%
19,955,126
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$400M 5.63%
13,650,835
– –
XOMA
7
DELISTED
Xoma
XOMA
$155M 2.18%
1,151,619
– –
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$137M 1.92%
1,941,304
+1,157,993
+148% +$78.6M
HALO icon
9
Halozyme
HALO
$9.87B
$94.4M 1.33%
6,297,026
-720,582
-10% -$9.27M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$303M
$59.5M 0.84%
4,791,179
– –
CERS icon
11
Cerus
CERS
$577M
$54.5M 0.77%
8,455,306
– –
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.43B
$50.9M 0.72%
6,699,979
– –
RPRX
13
DELISTED
Repros Therapeutics Inc.
RPRX
$50.8M 0.72%
2,778,654
– –
QCOR
14
DELISTED
QUESTCOR PHARMA INC
QCOR
$42.2M 0.6%
775,864
+230,018
+42% +$13.6M
ANAC
15
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$42M 0.59%
2,500,000
+1,623,537
+185% +$22.5M
GILD icon
16
Gilead Sciences
GILD
$165B
$41.8M 0.59%
556,108
-689,692
-55% -$48M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.6M 0.56%
2,380,074
+400,000
+20% +$6.84M
AEGR
18
DELISTED
Aegerion Pharmaceuticals
AEGR
$35.5M 0.5%
500,000
-320,275
-39% -$24.5M
ARWR icon
19
Arrowhead Research
ARWR
$12B
$33.5M 0.47%
3,090,000
-50,000
-2% -$400K
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$32M 0.45%
530,738
+228,994
+76% +$12.5M
DSCI
21
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$27.7M 0.39%
2,558,857
– –
CHTP
22
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$25.7M 0.36%
5,794,753
– –
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$25.4M 0.36%
796,662
– –
ICPT
24
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$24.8M 0.35%
362,847
– –
PGNX
25
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$22.4M 0.32%
4,200,000
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2013 Portfolio in Review

As of Q4 2013, Baker Bros. Advisors held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in DYAX CORPORATION worth $15.3M.

  • Baker Bros. Advisors's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
  • Baker Bros. Advisors's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
  • Baker Bros. Advisors fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
  • Baker Bros. Advisors opened 15 new positions and closed 6 in Q4 2013.
  • Baker Bros. Advisors's portfolio value rose 0.85% quarter-over-quarter to $7.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.